The U.S. biopharmaceutical industry is witnessing a significant transformation as contract development and manufacturing organizations (CDMOs) become increasingly important in supporting the production of complex biologic therapies. Growing demand for monoclonal antibodies, recombinant proteins, cell and gene therapies, and biosimilars has encouraged pharmaceutical and biotechnology companies...